bosentan anhydrous has been researched along with ACD-MPV in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Abman, SH; Kinsella, JP; Mandell, E | 1 |
| Shi, J; Song, LL; van den Anker, J; Wu, YE; Yang, XY; Zhang, W; Zhao, W | 1 |
| Amin, F; Kamran, A; Khalid, A; Kumari, V; Patel, N; Rafiq, N; Shaikh, AS; Tebha, SS | 1 |
| Luecke, C; McPherson, C | 1 |
| Dissaneevate, S; Janjindamai, W; Maneenil, G; Thatrimontrichai, A | 1 |
| Baba, T; Iijima, S; Ohishi, A; Ueno, D | 1 |
| Abman, SH; Gien, J; Roe, G; Seedorf, G; Tseng, N; Wolf, D | 1 |
| Beghetti, M; Cornelisse, P; Fineman, J; Gehin, M; Kusic-Pajic, A; Nowbakht, P; Pierce, CM; Steinhorn, RH | 1 |
| Bruni, A; Camerini, P; Radicioni, M | 1 |
| Datar, SA; Fineman, JR; Oishi, P | 1 |
| Ishida, F; Ishida, K; Kawakami, T; Kodama, Y; Matsuoka, K; Nakazawa, A; Takemura, T; Tao, K; Tsuchiya, K; Yoda, H | 1 |
5 review(s) available for bosentan anhydrous and ACD-MPV
| Article | Year |
|---|---|
Persistent pulmonary hypertension of the newborn.
Topics: Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Hypoxia; Infant; Infant, Newborn; Infant, Premature; Lung; Milrinone; Nitric Oxide; Oxygen; Persistent Fetal Circulation Syndrome; Pulmonary Alveoli; Pulmonary Surfactants; Risk; Sildenafil Citrate; Vascular Resistance; Vasodilator Agents | 2021 |
Oral drugs used to treat persistent pulmonary hypertension of the newborn.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Humans; Infant, Newborn; Off-Label Use; Persistent Fetal Circulation Syndrome; Randomized Controlled Trials as Topic; Sildenafil Citrate; Tadalafil | 2020 |
Treatment of Persistent Pulmonary Hypertension of the Newborn: Use of Pulmonary Vasodilators in Term Neonates.
Topics: Bosentan; Humans; Infant, Newborn; Milrinone; Nitric Oxide; Oxygen Inhalation Therapy; Persistent Fetal Circulation Syndrome; Prostaglandins; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2017 |
Hypertrophic pyloric stenosis following persistent pulmonary hypertension of the newborn: a case report and literature review.
Topics: Antihypertensive Agents; Atropine; Bosentan; Bronchodilator Agents; Female; High-Frequency Ventilation; Humans; Infant, Newborn; Meconium Aspiration Syndrome; Muscarinic Antagonists; Nitric Oxide; Nitric Oxide Donors; Nitroglycerin; Persistent Fetal Circulation Syndrome; Pyloric Stenosis, Hypertrophic; Sildenafil Citrate; Vasodilator Agents | 2018 |
Advances in the management of pediatric pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Child; Citrulline; Drug Therapy, Combination; Endothelium, Vascular; Hemodynamics; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Muscle Contraction; Persistent Fetal Circulation Syndrome; Phosphodiesterase 5 Inhibitors; Piperazines; PPAR gamma; Prostaglandins; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vascular Resistance; Vasoconstriction; Ventricular Function, Right | 2011 |
1 trial(s) available for bosentan anhydrous and ACD-MPV
| Article | Year |
|---|---|
Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial.
Topics: Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Female; Humans; Infant, Newborn; Male; Nitric Oxide; Persistent Fetal Circulation Syndrome; Respiration, Artificial; Sulfonamides; Treatment Failure; Treatment Outcome | 2016 |
5 other study(ies) available for bosentan anhydrous and ACD-MPV
| Article | Year |
|---|---|
Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital.
Topics: Bosentan; Child; Humans; Infant, Newborn; Nitric Oxide; Persistent Fetal Circulation Syndrome; Prospective Studies; Sildenafil Citrate; Tertiary Care Centers; Vasodilator Agents | 2022 |
Effect of bosentan therapy in persistent pulmonary hypertension of the newborn.
Topics: Administration, Oral; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Infant, Newborn; Male; Persistent Fetal Circulation Syndrome; Retrospective Studies; Sulfonamides; Treatment Outcome | 2018 |
Endothelin-1 decreases endothelial PPARĪ³ signaling and impairs angiogenesis after chronic intrauterine pulmonary hypertension.
Topics: Animals; Bosentan; Cells, Cultured; Endothelial Cells; Endothelin Receptor Antagonists; Endothelin-1; Humans; Infant, Newborn; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Persistent Fetal Circulation Syndrome; PPAR gamma; Pulmonary Artery; Receptors, Endothelin; Sheep; Signal Transduction; Sulfonamides | 2014 |
Combination therapy for life-threatening pulmonary hypertension in a premature infant: first report on bosentan use.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Nitric Oxide; Persistent Fetal Circulation Syndrome; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2011 |
Long survival of congenital alveolar capillary dysplasia patient with NO inhalation and epoprostenol: effect of sildenafil, beraprost and bosentan.
Topics: Administration, Inhalation; Bosentan; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epoprostenol; Fatal Outcome; Female; Follow-Up Studies; Humans; Infant, Newborn; Nitric Oxide; Persistent Fetal Circulation Syndrome; Piperazines; Platelet Aggregation Inhibitors; Pulmonary Alveoli; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Vasodilator Agents | 2012 |